Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ZBIO 
Zenas BioPharma, Inc. Common Stock (ZBIO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: ZBIO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $34.29
1 Year Target Price $34.29
| 5 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 2.1% | Avg. Invested days 29 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.14B USD | Price to earnings Ratio - | 1Y Target Price 34.29 |
Price to earnings Ratio - | 1Y Target Price 34.29 | ||
Volume (30-day avg) 7 | Beta - | 52 Weeks Range 5.83 - 29.73 | Updated Date 10/17/2025 |
52 Weeks Range 5.83 - 29.73 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -12.29 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1260.67% |
Management Effectiveness
Return on Assets (TTM) -47.94% | Return on Equity (TTM) -88.4% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 609940057 | Price to Sales(TTM) 76.04 |
Enterprise Value 609940057 | Price to Sales(TTM) 76.04 | ||
Enterprise Value to Revenue 40.66 | Enterprise Value to EBITDA - | Shares Outstanding 47110313 | Shares Floating 13161578 |
Shares Outstanding 47110313 | Shares Floating 13161578 | ||
Percent Insiders 29.87 | Percent Institutions 71.2 |
Upturn AI SWOT
Zenas BioPharma, Inc. Common Stock
Company Overview
History and Background
Zenas BioPharma is a global biopharmaceutical company committed to becoming a leader in the development and commercialization of meaningfully differentiated therapeutics for patients in need. Founded to address unmet medical needs, the company focuses on autoimmune diseases.
Core Business Areas
- Immunology: Focuses on developing therapies for autoimmune diseases.
Leadership and Structure
The leadership team consists of experienced professionals in the biopharmaceutical industry. Specifics on the team structure are typically available on the company's investor relations website and in SEC filings.
Top Products and Market Share
Key Offerings
- Obexelimab: An investigational XmAbu00ae-based bispecific antibody targeting CD19 and Fcu03b3RIIb. Currently in clinical development for autoimmune diseases. Market share is currently 0 as the product is not yet approved. Competitors include established therapies for autoimmune diseases from companies like Roche (Rituxan), Johnson & Johnson (Stelara), and AbbVie (Humira).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, stringent regulatory requirements, and intense competition. Growth is driven by increasing prevalence of diseases, technological advancements, and aging populations.
Positioning
Zenas BioPharma aims to differentiate itself through novel therapeutic approaches, particularly bispecific antibodies. Their competitive advantage relies on the potential efficacy and safety profiles of their pipeline assets.
Total Addressable Market (TAM)
The autoimmune disease market is substantial, projected to reach hundreds of billions of dollars. Zenas aims to capture a portion of this TAM with Obexelimab and other pipeline assets, positioning itself to address underserved patient populations.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach (bispecific antibodies)
- Experienced management team
- Focus on unmet medical needs in autoimmune diseases
- Potential for differentiated efficacy and safety
Weaknesses
- Dependence on pipeline progress
- High R&D costs
- Lack of currently marketed products
- Susceptible to clinical trial failures
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline through acquisitions or licensing
- Positive clinical trial results
- Approval and commercialization of Obexelimab
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established therapies
- Patent challenges
Competitors and Market Share
Key Competitors
- RHHBY
- JNJ
- ABBV
Competitive Landscape
Zenas BioPharma competes with established pharmaceutical companies and other biotechnology firms developing therapies for autoimmune diseases. Their advantage lies in their bispecific antibody technology and focus on specific unmet needs.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily measured by progress in clinical development and fundraising success.
Future Projections: Future growth depends on the successful development and commercialization of Obexelimab and other pipeline assets. Analyst estimates would be needed for specific revenue projections.
Recent Initiatives: Recent initiatives include advancing Obexelimab through clinical trials and exploring new therapeutic targets.
Summary
Zenas BioPharma is a clinical-stage biopharmaceutical company focused on developing treatments for autoimmune diseases using bispecific antibody technology. Their success hinges on the positive outcome of their clinical trials, specifically for Obexelimab. They face competition from established players in the pharmaceutical industry and must navigate regulatory hurdles. Their current financial health depends on continued fundraising and efficient use of capital. Their focus on unmet medical needs and innovative technology provide potential for future growth if clinical trials are positive.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It is not investment advice. Investment decisions should be made based on individual circumstances and consultation with a qualified financial advisor. Market share estimates are approximations.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Zenas BioPharma, Inc. Common Stock
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2024-09-13 | CEO & Chairman of the Board Mr. Leon Oliver Moulder Jr., M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 130 | Website https://zenasbio.com |
Full time employees 130 | Website https://zenasbio.com | ||
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc"RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.